Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Change in Accured Expenses data on file, last reported at -$79000.0 in Q4 2025.

• For the quarter ending Q4 2025, Change in Accured Expenses rose 89.38% year-over-year to -$79000.0; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 148.3% YoY), and the FY2025 full-year result was $3.6 million, up 148.3% from the prior year.
• Change in Accured Expenses eased to -$79000.0 in Q4 2025, from $4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $20.7 million in Q4 2023 to a low of -$6.7 million in Q2 2025.
• A 5-year average of $1.7 million and a median of $58000.0 in 2021 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 1249.74% in 2022, while the deepest fall reached 2150.56% in 2022.
• Tracing STRO's Change in Accured Expenses over 5 years: stood at $5.2 million in 2021, then jumped by 45.1% to $7.6 million in 2022, then jumped by 172.68% to $20.7 million in 2023, then slumped by 103.59% to -$744000.0 in 2024, then soared by 89.38% to -$79000.0 in 2025.
• Business Quant data shows STRO's Change in Accured Expenses at -$79000.0 in Q4 2025, $4.8 million in Q3 2025, and -$6.7 million in Q2 2025.